BioNTech SE’s Strategic Acquisition of CureVac Bolsters mRNA Therapeutics and Growth Potential

BMO Capital analyst Evan Seigerman has maintained their bullish stance on BNTX stock, giving a Buy rating today.

Evan Seigerman has given his Buy rating due to a combination of factors that highlight BioNTech SE’s strategic growth and potential. The acquisition of CureVac is seen as a strategic move that not only expands BioNTech’s portfolio in personalized and off-the-shelf cancer vaccines but also resolves ongoing litigation concerns. This acquisition is expected to enhance BioNTech’s capabilities in developing novel mRNA therapeutics, aligning well with its existing platforms such as FixVac and iNeST.
Furthermore, the acquisition signifies confidence in BioNTech’s future growth, as it provides access to CureVac’s scalable mRNA manufacturing system. This system is anticipated to support BioNTech’s growth plans in mRNA therapeutics, offering potential benefits in both early commercial assets and clinical trials. Seigerman’s rating also reflects the expectation of a stable COVID-19 vaccine business in the near to medium term, alongside an emerging pipeline with several catalysts that could drive share upside. Overall, the strategic acquisition and the ability to deploy significant capital for business development underpin the Buy rating.

In another report released today, Deutsche Bank also maintained a Buy rating on the stock with a $140.00 price target.

Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BNTX in relation to earlier this year.